Ram Yogev

Summary

Affiliation: Northwestern University
Country: USA

Publications

  1. ncbi request reprint Stavudine, nevirapine and ritonavir in stable antiretroviral therapy-experienced children with human immunodeficiency virus infection
    Ram Yogev
    Division of Infectious Diseases, Children s Memorial Hospital, Chicago, IL 60614 3394, USA
    Pediatr Infect Dis J 21:119-25. 2002
  2. pmc Early initiation of lopinavir/ritonavir in infants less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacy
    Ellen Gould Chadwick
    Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
    Pediatr Infect Dis J 28:215-9. 2009
  3. pmc Long-term outcomes for HIV-infected infants less than 6 months of age at initiation of lopinavir/ritonavir combination antiretroviral therapy
    Ellen G Chadwick
    Division of Infectious Diseases, Children s Memorial Hospital, Northwestern University s Feinberg School of Medicine, Chicago, Illinois, USA
    AIDS 25:643-9. 2011
  4. ncbi request reprint Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results
    Ellen G Chadwick
    Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA
    AIDS 22:249-55. 2008
  5. ncbi request reprint Management of brain abscesses in children
    Ram Yogev
    Children s Memorial Hospital, Chicago, IL, USA
    Pediatr Infect Dis J 23:157-9. 2004
  6. ncbi request reprint Ritonavir-based highly active antiretroviral therapy in human immunodeficiency virus type 1-infected infants younger than 24 months of age
    Ellen Gould Chadwick
    Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
    Pediatr Infect Dis J 24:793-800. 2005
  7. doi request reprint Pharmacokinetics and distribution of linezolid in cerebrospinal fluid in children and adolescents
    Ram Yogev
    Department of Pediatrics, Northwestern University Medical School, Chicago, IL, USA
    Pediatr Infect Dis J 29:827-30. 2010
  8. pmc Single-dose safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, in HIV-infected children
    Ram Yogev
    Division of Infectious Diseases, Children s Memorial Hospital, 2300 Children s Plaza, Box 155, Chicago, IL 60614, USA
    Antimicrob Agents Chemother 49:336-41. 2005
  9. ncbi request reprint The role of protease inhibitor therapy in children with HIV infection
    Patrick J Gavin
    Division of Infectious Diseases, Children s Memorial Hospital and the Departments of Pediatrics, Northwestern University Medical School, Chicago, Illinois 60614 3394, USA
    Paediatr Drugs 4:581-607. 2002
  10. ncbi request reprint Indirect protection of adults from rotavirus by pediatric rotavirus vaccination
    Evan J Anderson
    Department of Pediatrics, Northwestern University Feinberg School of Medicine, Divisions of Infectious Diseases, Chicago, Illinois, USA
    Clin Infect Dis 56:755-60. 2013

Collaborators

Detail Information

Publications43

  1. ncbi request reprint Stavudine, nevirapine and ritonavir in stable antiretroviral therapy-experienced children with human immunodeficiency virus infection
    Ram Yogev
    Division of Infectious Diseases, Children s Memorial Hospital, Chicago, IL 60614 3394, USA
    Pediatr Infect Dis J 21:119-25. 2002
    ..Aim. To evaluate the safety, tolerance, antiviral activity and immunologic changes after the change to a three drug combination...
  2. pmc Early initiation of lopinavir/ritonavir in infants less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacy
    Ellen Gould Chadwick
    Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
    Pediatr Infect Dis J 28:215-9. 2009
    ....
  3. pmc Long-term outcomes for HIV-infected infants less than 6 months of age at initiation of lopinavir/ritonavir combination antiretroviral therapy
    Ellen G Chadwick
    Division of Infectious Diseases, Children s Memorial Hospital, Northwestern University s Feinberg School of Medicine, Chicago, Illinois, USA
    AIDS 25:643-9. 2011
    ..To investigate the longitudinal pharmacokinetics, safety and efficacy of lopinavir/ritonavir (LPV/r) in HIV-infected infants initiating combination antiretroviral therapy (cART) between 2 weeks and 6 months of age...
  4. ncbi request reprint Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results
    Ellen G Chadwick
    Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA
    AIDS 22:249-55. 2008
    ..To investigate pharmacokinetics, safety and efficacy of lopinavir/ritonavir (LPV/r)-based therapy in HIV-1-infected infants 6 weeks to 6 months of age...
  5. ncbi request reprint Management of brain abscesses in children
    Ram Yogev
    Children s Memorial Hospital, Chicago, IL, USA
    Pediatr Infect Dis J 23:157-9. 2004
  6. ncbi request reprint Ritonavir-based highly active antiretroviral therapy in human immunodeficiency virus type 1-infected infants younger than 24 months of age
    Ellen Gould Chadwick
    Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
    Pediatr Infect Dis J 24:793-800. 2005
    ..Few data are available regarding clinical outcomes or dosing requirements for the protease inhibitor ritonavir in human immunodeficiency virus (HIV)-infected children younger than under 24 months of age...
  7. doi request reprint Pharmacokinetics and distribution of linezolid in cerebrospinal fluid in children and adolescents
    Ram Yogev
    Department of Pediatrics, Northwestern University Medical School, Chicago, IL, USA
    Pediatr Infect Dis J 29:827-30. 2010
    ..Two studies in hydrocephalic children and adolescents were performed to assess the penetration of linezolid into cerebrospinal fluid and its relation to meningeal inflammation...
  8. pmc Single-dose safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, in HIV-infected children
    Ram Yogev
    Division of Infectious Diseases, Children s Memorial Hospital, 2300 Children s Plaza, Box 155, Chicago, IL 60614, USA
    Antimicrob Agents Chemother 49:336-41. 2005
    ..Considerable interpatient variability was seen for all pharmacokinetic parameters of amprenavir. The results of this study suggest that 20 mg of amprenavir/kg administered twice a day should be used in future pediatric studies...
  9. ncbi request reprint The role of protease inhibitor therapy in children with HIV infection
    Patrick J Gavin
    Division of Infectious Diseases, Children s Memorial Hospital and the Departments of Pediatrics, Northwestern University Medical School, Chicago, Illinois 60614 3394, USA
    Paediatr Drugs 4:581-607. 2002
    ..PI-containing HAART has transformed HIV infection into a chronic illness, and HIV-infected children now live longer...
  10. ncbi request reprint Indirect protection of adults from rotavirus by pediatric rotavirus vaccination
    Evan J Anderson
    Department of Pediatrics, Northwestern University Feinberg School of Medicine, Divisions of Infectious Diseases, Chicago, Illinois, USA
    Clin Infect Dis 56:755-60. 2013
    ..Whether this protection extends to adults is unknown...
  11. pmc Higher incidence of perineal community acquired MRSA infections among toddlers
    Alexis C McCullough
    The University of Toledo College of Medicine, OH 43614, USA
    BMC Pediatr 11:96. 2011
    ..A six-fold increase in pediatric MRSA infections, prompted us to examine the clinical profile of children with MRSA infections seen at Mercy Children's Hospital, Toledo, Ohio and to characterize the responsible strains...
  12. ncbi request reprint Bacterial meningitis in children: critical review of current concepts
    Ram Yogev
    Feinberg School of Medicine, Children s Memorial Hospital, Chicago, Illinois 60614, USA
    Drugs 65:1097-112. 2005
    ....
  13. pmc Neonatal sepsis caused by Streptococcus bovis variant (biotype II/2): report of a case and review
    Patrick J Gavin
    Division of Infectious Diseases, Children s Memorial Hospital and Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
    J Clin Microbiol 41:3433-5. 2003
    ..bovis. We report a 3-day-old neonate with bacteremia and meningitis caused by S. bovis variant (S. bovis biotype II/2) and review the literature...
  14. ncbi request reprint A rational approach to the management of ventricular shunt infections
    Evan J Anderson
    Children s Memorial Hospital, Chicago, IL, USA
    Pediatr Infect Dis J 24:557-8. 2005
  15. ncbi request reprint Linezolid for the treatment of complicated skin and skin structure infections in children
    Ram Yogev
    Children s Memorial Hospital, Chicago, IL, USA
    Pediatr Infect Dis J 22:S172-7. 2003
    ..Many pathogens are developing decreased susceptibility to currently used antibiotics, increasing the need for new therapies. Linezolid is well-tolerated and effective in the treatment of these infections in adults...
  16. pmc Quantification of human immunodeficiency virus type 1 proviral DNA by using TaqMan technology
    Yuqi Zhao
    Children s Memorial Institute for Education and Research, Northwestern University, Chicago, Illinois 60614, USA
    J Clin Microbiol 40:675-8. 2002
    ..Viral RNA levels, when at a stable state, were highly correlated with proviral DNA levels in 80 specimens of 18 HIV-infected children...
  17. doi request reprint Differential gene expression of soluble CD8+ T-cell mediated suppression of HIV replication in three older children
    Ben Z Katz
    Department of Pediatrics, Northwestern University Feinberg School of Medicine and Children s Memorial Hospital, Chicago, Illinois 60614, USA
    J Med Virol 83:24-32. 2011
    ..Our data also lends some support to the recent identification of CAF with exosomes secreted by CD8+ T-cells...
  18. ncbi request reprint Mycobacterium gordonae bacteremia in an asymptomatic adolescent with acquired immunodeficiency syndrome
    Robert Garofalo
    Division of Infectious Diseases, Children s Memorial Hospital, Chicago, IL, USA
    Pediatr Infect Dis J 22:569-70. 2003
    ..Illness related to M. gordonae infection ranges from localized infections to rare cases of disseminated disease. This report describes treatment of the first case of occult M. gordonae bacteremia in an adolescent with AIDS...
  19. pmc Recombinant glycoprotein vaccines for human immunodeficiency virus-infected children and their effects on viral quasispecies
    Shaffiq M Essajee
    Department of Pediatrics, Division of Infectious Diseases, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA
    Clin Diagn Lab Immunol 9:79-82. 2002
    ..These results suggest that the immune response elicited by RGP vaccines does not exert a significant selection pressure on the viral quasispecies and therefore may not be helpful in changing the course of the disease...
  20. ncbi request reprint Evaluation of multiple drug therapy in human immunodeficiency virus-infected pediatric patients
    Jennifer R King
    Division of Clinical Pharmacology, University of Alabama at Birmingham, 35294, USA
    Pediatr Infect Dis J 22:239-44. 2003
    ..The clinical benefits of this regimen are often accompanied by increased toxicities. We report the safety and tolerance of multiple drug therapy in HIV-infected children...
  21. ncbi request reprint Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021
    Ross E McKinney
    Department of Pediatrics, Duke University Medical Center, Box 3461, Durham, NC 27710, USA
    Pediatrics 120:e416-23. 2007
    ..Compliance with complex antiretroviral therapy regimens is a problem for HIV-1-infected children and their families. Simple, safe, and effective regimens are important for long-term therapeutic success...
  22. ncbi request reprint Pharmacokinetic characteristics of ritonavir, zidovudine, lamivudine, and stavudine in children with human immunodeficiency virus infection
    Courtney V Fletcher
    Pediatric AIDS Clinical Trials Group and the Department of Clinical Pharmacy, University of Colorado Health Sciences Center, Denver 80262, USA
    Pharmacotherapy 24:453-9. 2004
    ..To evaluate and describe the parameters and characteristics of different drug regimens in children infected with human immunodeficiency virus (HIV)...
  23. doi request reprint Long-term safety and efficacy results of once-daily emtricitabine-based highly active antiretroviral therapy regimens in human immunodeficiency virus-infected pediatric subjects
    Xavier Saez-Llorens
    Infectious Disease Department, Hospital del Nino, Panama City, Panama
    Pediatrics 121:e827-35. 2008
    ....
  24. pmc Structured treatment interruptions (STIs) in HIV-1 infected pediatric populations increases interferon gamma production and reduces viremia
    William Borkowsky
    NYU School of Medicine, New York, NY, USA
    Vaccine 26:3086-9. 2008
    ..This allowed us to conclude that exposure to autologous virus increased HIV-specific immune responses and decreased HIV RNA were seen in those who have had >13 interruptions, with STI intervals that exceeded 27 days...
  25. pmc Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors
    Brian L Robbins
    St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Antimicrob Agents Chemother 52:3276-83. 2008
    ....
  26. pmc Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents
    Juan C Salazar
    Connecticut Children s Medical Center, University of Connecticut School of Medicine, Hartford, Connecticut 06106, USA
    AIDS 22:1789-98. 2008
    ..To evaluate the efficacy, safety and tolerability of ritonavir-boosted tipranavir (TPV/r) in HIV-1-infected pediatric patients...
  27. ncbi request reprint Growth in human immunodeficiency virus-infected children receiving ritonavir-containing antiretroviral therapy
    Sharon A Nachman
    Department of Pediatrics, State University of New York Health Science Center at Stony Brook, Stony Brook, NY 11794 8111, USA
    Arch Pediatr Adolesc Med 156:497-503. 2002
    ..Human immunodeficiency virus (HIV)-infected children often suffer from impaired growth. Highly active antiretroviral therapy (HAART) successfully reduces HIV 1 (HIV-1) RNA to 400 copies/mL or less in many children...
  28. ncbi request reprint Virologic response to potent antiretroviral therapy and modeling of HIV dynamics in early pediatric infection
    Paul Palumbo
    Department of Pediatrics, University of Medicine and Dentistry New Jersey Medical School, Newark, NJ, USA
    J Infect Dis 196:23-9. 2007
    ..Similar studies are needed in pediatric populations, in whom differing dynamics might translate into age-specific treatment approaches...
  29. doi request reprint Planned multiple exposures to autologous virus in HIV type 1-infected pediatric populations increases HIV-specific immunity and reduces HIV viremia
    William Borkowsky
    NYU School of Medicine, New York, New York 10016, USA
    AIDS Res Hum Retroviruses 24:401-11. 2008
    ..Other studies may have failed due to an insufficient number of exposures to HIV; most of the studies had fewer than six drug interruptions...
  30. pmc Rapid human immunodeficiency virus decay in highly active antiretroviral therapy (HAART)-experienced children after starting mega-HAART
    Nottasorn Plipat
    Division of Infectious Diseases, Department of Pediatrics, Siriraj Hospital, Mahidol University, Bangkok, Thailand
    J Virol 78:11272-5. 2004
    ..026d(-1), range = -0.005 to 0.206, t2(1/2) = 9.316d). This indicates that mega-HAART can provide potent therapy among heavily experienced pediatric patients...
  31. ncbi request reprint Neuropsychological functioning and viral load in stable antiretroviral therapy-experienced HIV-infected children
    Rita J Jeremy
    Pediatric Clinical Research Center, Department of Pediatrics, School of Medicine, University of California San Francisco, 505 Parnassus Ave, San Francisco, CA 94143 0105, USA
    Pediatrics 115:380-7. 2005
    ..Neuropsychological functioning and its correlation with viral load were investigated for previously treated HIV-infected children who underwent a change in treatment regimen...
  32. ncbi request reprint Switch from ritonavir to indinavir in combination therapy for HIV-1-infected children
    Stephen I Pelton
    Boston Medical Center, Boston, MA 02118, USA
    Clin Infect Dis 40:1181-7. 2005
    ....
  33. ncbi request reprint Balancing the upside and downside of antiretroviral therapy in children
    Ram Yogev
    JAMA 293:2272-4. 2005
  34. ncbi request reprint Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403
    Jennifer R King
    University of Alabama at Birmingham, Birmingham, USA
    Pediatr Infect Dis J 24:880-5. 2005
    ..We tested the efficacy, tolerability and pharmacokinetics of 2 combination therapies containing an NRTI, protease inhibitors +/- a nonnucleoside reverse transcription inhibitor (NNRTI)...
  35. ncbi request reprint Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children
    Sheldon L Kaplan
    Baylor College of Medicine and Texas Children s Hospital, 6621 Fannin Street, MC3 2371, Feigin Center No 1150, Houston, TX 77030, USA
    Pediatr Infect Dis J 22:677-86. 2003
    ..Pediatric infections caused by resistant Gram-positive infections are an increasing concern with limited treatment options. Linezolid, a new oxazolidinone, is active against staphylococci, streptococci and enterococci...
  36. ncbi request reprint A behavioral and cognitive profile of clinically stable HIV-infected children
    Molly L Nozyce
    Department of Pediatrics, Bronx Lebanon Hospital Center, Bronx, New York, USA
    Pediatrics 117:763-70. 2006
    ..The purpose of this research was to characterize behavioral and cognitive profiles of clinically and immunologically stable antiretroviral-experienced HIV-infected children...
  37. ncbi request reprint Pharmacokinetics of antiretrovirals administered to HIV-infected children via gastrostomy tube
    Jennifer R King
    Division of Clinical Pharmacology, University of Alabama at Birmingham, 1530 3rd Avenue South, Birmingham, AL 35294, USA
    HIV Clin Trials 5:288-93. 2004
    ..The goal of this pilot study was to describe the pharmacokinetic characteristics of protease inhibitors (PIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs) when administered to HIV-infected children via g-tube...
  38. ncbi request reprint Comparison of atovaquone and azithromycin with trimethoprim-sulfamethoxazole for the prevention of serious bacterial infections in children with HIV infection
    Walter T Hughes
    Department of Infectious Diseases, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Clin Infect Dis 40:136-45. 2005
    ....
  39. ncbi request reprint Single-dose pharmacokinetics of enteric-coated didanosine in HIV-infected children
    Jennifer R King
    The University of Alabama at Birmingham, Birmingham, Ala, USA
    Antivir Ther 7:267-70. 2002
    ....
  40. ncbi request reprint Antibody responses to hepatitis A virus vaccine in HIV-infected children with evidence of immunologic reconstitution while receiving highly active antiretroviral therapy
    Adriana Weinberg
    Department of Pediatrics and Medicine, University of Colorado Health Sciences Center, Denver, Colorado, USA
    J Infect Dis 193:302-11. 2006
    ..We investigated the safety and immunogenicity of 2 doses of hepatitis A virus (HAV) vaccine followed by a booster dose in HIV-infected children receiving stable highly active antiretroviral therapy...
  41. ncbi request reprint The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis
    Sharon Nachman
    Department of Pediatrics, Stony Brook University, Stony Brook, NY 11794 8111, USA
    Pediatrics 115:e488-94. 2005
    ....
  42. doi request reprint Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age
    Terry Nolan
    School of Population Health, University of Melbourne and Murdoch Children s Research Institute, Carlton, Melbourne, Victoria 3010, Australia
    Pediatrics 121:508-16. 2008
    ..This study evaluated the safety, tolerability, and immunogenicity of live attenuated influenza vaccine administered concurrently with measles-mumps-rubella vaccine and varicella vaccine to healthy children 12 to 15 months of age...
  43. ncbi request reprint Opportunities to prevent HIV transmission in newborns
    Ram Yogev
    Pediatrics 118:436-7; author reply 437. 2006